Anita Ciarleglio, B.S., Ph.D.
Dr. Ciarleglio received her B.S. in pharmacy from St. Louis College of Pharmacy, and her Ph.D. in Pharmacology at St. Louis University School of Medicine. She is licensed as a registered pharmacist in Hawaii. She subsequently performed postdoctoral work at St. Louis and at the University of Miami School of Medicine. She has held many professional and instructional positions, notably conducting in-depth continuing education programs for pharmacists through Pacific Seminars Inc. and serving as an ambulatory care clinical pharmacist at Kaiser Permanente. Dr. Ciarleglio has instructed hundreds of students each semester through statewide distance-learning programs, as well as being highly active in several community education programs and pharmacy technology programs for the education of pharmacy technicians. She has been with the College of Pharmacy since February 2007. Previous to acceptance of the inaugural class, and was instrumental in coordinating the DKICP curriculum. She has taught many didactic courses since then and also established a practice site at Maui Memorial Medical Center in Acute Medicine where she cared for patients and mentors students in their Introductory and Advanced Pharmacy Practice Experiences. She also developed the first Community Pharmacy Residency Program in the State of Hawaii, which was funded by a United States Department of Education grant for Applied Rural Science and Clinical Pharmacy Training, and was the Residency Program Director. To date, five residents have completed the program. She also established and participated in a longitudinal rotation on medication safety in the elderly on Maui, under a USDA-funded program for Medication Safety Education for Elderly in Rural Areas. Recently Dr. Ciarleglio was a co-investigator on a $14 million federal grant from the Center for Medicare/Medicaid Services. This program, titled “Pharm2Pharm,” was designed to improve care and reduce costs by impacting medication-related hospitalizations and Emergency Room visits for high-risk patients.